David A. Siegel Oncocyte Corp Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.15 - $2.25 $433,664 - $848,475	-377,100 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$2.04 - $3.59 $741,744 - $1.31 Million	-363,600 Reduced 49.09%	377,100 $818,000
Q3 2021 Nov 15, 2021	BUY	$3.53 - $5.89 $279,929 - $467,077	79,300 Added 11.99%	740,700 $2.64 Million
Q2 2021 Aug 16, 2021	BUY	$3.77 - $6.0 $422,994 - $673,200	112,200 Added 20.43%	661,400 $3.8 Million
Q1 2021 May 17, 2021	BUY	$2.39 - $6.5 $1.31 Million - $3.57 Million	549,200 New	549,200 $2.85 Million

Q3 2020 Nov 16, 2020	SELL	$1.2 - $1.89 $51,720 - $81,459	-43,100 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.91 - $3.45 $82,321 - $148,695	43,100 New	43,100 $82,000

1.16M

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $350M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.